SCHEMBL1320587

SCHEMBL1320587

CC(C)(C)OC(=O)c1cc[nH]c1OB(O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
RAB9A P51151 2/20 0.31
NPC1 O15118 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
CA14 Q9ULX7 1/20 0.31
EGFR P00533 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624330 0.78 RAB9A (0.33) ELANEADRA1AADRA1BRAB9ANPC1
SCHEMBL6017086 0.76 ADRA1A (0.33) ADRA1AADRA1BRAB9ANPC1SMN1; SMN2
SCHEMBL1566864 0.75 CA12 (0.38) ADRA1AADRA1BRAB9ANPC1SMN1; SMN2
SCHEMBL15567828 0.75 RAB9A (0.38) ADRA1AADRA1BRAB9ANPC1SMN1; SMN2
SCHEMBL163017 0.75 CA12 (0.35) ELANEADRA1AADRA1BRAB9ANPC1
SCHEMBL8562952 0.73 ALDH1A1 (0.38) ADRA1AADRA1BRAB9ANPC1SMN1; SMN2
SCHEMBL28816343 0.71 ALDH1A1 (0.45) ADRA1AADRA1BRAB9ANPC1SMN1; SMN2
SCHEMBL28587355 0.71 ALDH1A1 (0.36) ADRA1AADRA1BALDH1A1
SCHEMBL18703898 0.70 ADRA1A (0.34) ADRA1AADRA1BRAB9ANPC1SMN1; SMN2
SCHEMBL3801958 0.69 ALDH1A1 (0.39) SMN1; SMN2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321299-B1 PYRIDONS AS PDK1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-02-24 EP disclosed
US-8637549-B2 Pyridons as PDK1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-28 US disclosed
US-20110313156-A1 HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
US-20110269958-A1 PYRIDONS AS PDK1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2323986-A2 HETOEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS Boehringer Ingelheim International GmbH (DE) 2011-05-25 EP disclosed
EP-2321299-A2 PYRIDONS AS PDK1 INHIBITORS Boehringer Ingelheim International GmbH (DE) 2011-05-18 EP disclosed
WO-2010007114-A2 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-21 WO disclosed
WO-2010007116-A2 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-21 WO disclosed
US-5574017-A Antibacterial agents GUTHEIL WILLIAM G (US) 1996-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313156-A1 HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS PDK2, PDK4, CCNH ELANE 3078/4885ADRA1A 4476/4885ADRA1B 4689/4885
US-20110269958-A1 PYRIDONS AS PDK1 INHIBITORS PDK1, PDK2, PDK4 ELANE 4830/4885ADRA1A 2192/4885ADRA1B 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.